DexCom Target of Unusually Large Options Trading (NASDAQ:DXCM)

DexCom, Inc. (NASDAQ:DXCM - Get Free Report) was the target of unusually large options trading on Thursday. Stock investors acquired 10,495 call options on the company. This represents an increase of approximately 87% compared to the typical daily volume of 5,616 call options.

Insider Buying and Selling

In related news, EVP Matthew Vincent Dolan sold 1,990 shares of the business's stock in a transaction on Monday, April 15th. The stock was sold at an average price of $137.81, for a total transaction of $274,241.90. Following the sale, the executive vice president now owns 42,377 shares in the company, valued at approximately $5,839,974.37. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, EVP Sadie Stern sold 20,321 shares of the company's stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $133.61, for a total transaction of $2,715,088.81. Following the transaction, the executive vice president now directly owns 80,441 shares of the company's stock, valued at approximately $10,747,722.01. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Matthew Vincent Dolan sold 1,990 shares of the company's stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $137.81, for a total value of $274,241.90. Following the transaction, the executive vice president now directly owns 42,377 shares in the company, valued at $5,839,974.37. The disclosure for this sale can be found here. Insiders have sold 189,375 shares of company stock worth $25,530,859 in the last 90 days. Insiders own 0.41% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. DSM Capital Partners LLC bought a new position in shares of DexCom in the 4th quarter valued at about $28,000. Riverview Trust Co purchased a new position in shares of DexCom during the first quarter worth approximately $32,000. Valley National Advisers Inc. increased its position in shares of DexCom by 73.0% during the fourth quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company's stock worth $30,000 after acquiring an additional 103 shares during the period. MV Capital Management Inc. increased its position in shares of DexCom by 99.3% during the fourth quarter. MV Capital Management Inc. now owns 277 shares of the medical device company's stock worth $34,000 after acquiring an additional 138 shares during the period. Finally, Smithfield Trust Co increased its position in shares of DexCom by 103.1% during the fourth quarter. Smithfield Trust Co now owns 325 shares of the medical device company's stock worth $40,000 after acquiring an additional 165 shares during the period. Hedge funds and other institutional investors own 97.75% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the company. Citigroup boosted their price objective on DexCom from $148.00 to $161.00 and gave the stock a "buy" rating in a report on Wednesday, April 3rd. StockNews.com lowered DexCom from a "buy" rating to a "hold" rating in a report on Tuesday. Royal Bank of Canada began coverage on DexCom in a report on Tuesday, March 12th. They issued an "outperform" rating and a $165.00 target price for the company. UBS Group upped their target price on DexCom from $153.00 to $163.00 and gave the company a "buy" rating in a report on Wednesday, April 10th. Finally, Raymond James upped their target price on DexCom from $147.00 to $151.00 and gave the company a "strong-buy" rating in a report on Tuesday, January 23rd. Three research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $141.40.

DexCom Trading Up 0.1 %

Shares of NASDAQ DXCM traded up $0.14 during trading hours on Thursday, hitting $138.01. The company's stock had a trading volume of 4,198,985 shares, compared to its average volume of 2,977,786. The company has a debt-to-equity ratio of 1.18, a quick ratio of 2.48 and a current ratio of 2.84. The stock has a market cap of $54.66 billion, a price-to-earnings ratio of 105.25, a P/E/G ratio of 2.30 and a beta of 1.20. DexCom has a 12 month low of $74.75 and a 12 month high of $142.00. The business has a 50-day simple moving average of $130.58 and a 200-day simple moving average of $117.88.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings data on Thursday, February 8th. The medical device company reported $0.50 EPS for the quarter, topping the consensus estimate of $0.43 by $0.07. The business had revenue of $1.03 billion during the quarter, compared to analyst estimates of $1.02 billion. DexCom had a net margin of 14.95% and a return on equity of 28.31%. DexCom's quarterly revenue was up 26.9% compared to the same quarter last year. During the same period last year, the business posted $0.34 earnings per share. On average, analysts anticipate that DexCom will post 1.76 earnings per share for the current fiscal year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.